Theranexus announced the initial results of their Phase I/II clinical trial for juvenile Batten disease (CLN3). After a 9-week course of Batten-1 with the maximum dose of 600 mg/day, the first results of the Phase I/II trial enrolling six patients with juvenile Batten disease (CLN3) aged 17 and over showed good patient safety and tolerability, and a pharmacokinetic profile in line with expectations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.135 EUR | +1.34% | +8.10% | +1.34% |
Apr. 19 | Theranexus: share price rises following promising trial results | CF |
Mar. 11 | Theranexus: CEO takes over as Chairman of the Board | CF |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.34% | 9.4M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ALTHX Stock
- News Theranexus
- Theranexus Announces the Initial Results of Their Phase I/II Clinical Trial for Juvenile Batten Disease